AZD5863AZD5863-mediatedCLDN18.2esophageal adenocarcinoma
…raftment of immune populations in a humanized model.Conclusions AZD5863 mediates potent anti-tumor activity in vitro and in vivo, while…
4articles mentioning drugs
10drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: CLDN18.2 ×
CLDN18.2
This drug is selected. Its supporting articles are shown below.
Articles mentioning CLDN18.2
4 articles · page 1 of 1CLDN18.2metastatic gastric cancerMalignant effusion
…s (p=0.044) with higher expression levels (p=0.02). Conversely, CLDN18.2 positivity was lower in CBs versus primary tumours (p=0.004). M…
AZD6422CLDN18.2aCD20esophageal cancers
…reen S, Broggi, MAS, Hatke AL, et al. Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2…
MRTX1133CLDN18.2O-GlcNAcylated CLDN18.2KPC micepancreatic ductal adenocarcinomagastric and gastro-oesophageal junction cancersPDAC
…on and suppresses tumour progression. Therapeutically, low-dose MRTX1133 (KRASG12D inhibitor) reduces O-GlcNAcylation and synergises wit…